| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
3 companies
Brad Hively is Director at TOIIW and has filed Form 4s across 3 companies. Brad Hively's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.2M at current prices.
Historically, Brad Hively's trades have earned a strong insider score of 79/100 across 8 rated trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +71.9%.
The biggest single holding is STLN (~$2.6M) as Director. The STLN filings lean toward selling, a net 298,853 shares.
Brad Hively has 20 Form 4 filings on record from November 2021 to August 2026, across 3 companies: Director at Starling Oncology (STLN), 2026; Director at The Oncology Institute (TOIIW), 2026; Director at Oncology Institute (TOI), 2021–2025.
The 38 reported transactions were 10 stock awards, 7 open-market sales, 6 option exercises and 5 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $59K and 6 sales worth about $7.9M.
The largest open-market purchase was 300,000 shares of TOI at an average $0.17 on December 2, 2024, about $50K. Twelve months later TOI was up 1804%.
The largest open-market sale was 1,976,137 shares of TOI at an average $2.87 on June 3, 2025, about $5.7M. Twelve months later TOI was up 49%.
1 of the 6 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 5 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | STLN Starling Oncology, Inc. | Director | Sell10b5-1 | 298,853 | $6.51 | $1,946,310.05 | -42.0% | - | - | |
| Dec 15, 2025 | TOI Oncology Institute, Inc. | Director | Sell | 13,333 | $3.77 | $50,290.74 | -1.9% | -9.5% | - | |
| Aug 19, 2025 | TOI Oncology Institute, Inc. | Director | Sell | 20,221 | $4.06 | $82,097.26 | -3.1% | -1.3% | - | |
| Jun 3, 2025 | TOI Oncology Institute, Inc. | Director | Sale+OE | 1,976,137 | $2.87 | $5,672,106.03 | -76.6% | +1.6% | +49.4% | |
| Mar 26, 2025 | TOI Oncology Institute, Inc. | Director | Buy | 9,056 | $1.04 | $9,433.64 | +1.4% | +94.2% | +156.2% | |
| Dec 2, 2024 | TOI Oncology Institute, Inc. | Director | Buy | 300,000 | $0.17 | $50,000.00 | +81.8% | +365.6% | +1803.5% | |
| Nov 17, 2023 | TOI Oncology Institute, Inc. | Director | Sale+OE | 25,000 | $2.24 | $56,000.00 | -3.5% | -22.3% | -92.2% | |
| Nov 13, 2023 | TOI Oncology Institute, Inc. | Director | Sale+OE | 47,000 | $2.52 | $118,581.00 | -6.1% | -22.0% | -88.6% |